Co-treatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells

PURPOSE: We determined the effects of vorinostat [suberoylanalide hydroxamic acid (SAHA)] and/or MK-0457 (VX-680), an Aurora kinase inhibitor on the cultured human (HL-60, OCI-AML3 and K562) and primary acute (AML) and chronic myelogenous leukemia (CML), as well as on the murine pro-B BaF3 cells wit...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Fiskus, Warren, Wang, Yongchao, Joshi, Rajeshree, Rao, Rekha, Yang, Yonghua, Chen, Jianguang, Kolhe, Ravindra, Balusu, Ramesh, Eaton, Kelly, Lee, Pearl, Ustun, Celalettin, Jillella, Anand, Buser, Carolyn A., Peiper, Stephen, Bhalla, Kapil
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2008
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2665710/
https://ncbi.nlm.nih.gov/pubmed/18829489
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0721
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg